Georgia's Online Cancer Information Center

Unknown Primary Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Unknown Primary
Cancer Type = Unknown Primary
There are currently 208 active Unknown Primary clinical trials in Georgia.
1.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03800693
Protocol IDs
Winship4468-18
NCI-2018-02241
IRB00106610
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04115631
Protocol IDs
EA4181
NCI-2019-05536
EA4181
Treatment Sites (2)
4.
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04505826
Protocol IDs
OP-1250-001
NCI-2020-13877
5.
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03978689
Protocol IDs
Cue-101-01
NCI-2019-04589
Treatment Sites (1)
6.
A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05199272
Protocol IDs
23ME-00610-CLIN-001
NCI-2022-03572
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
8.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
9.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery
Cancer Type
Unknown Primary
NCT ID
NCT04195399
Protocol IDs
ARST1921
ARST1921
NCI-2019-07498
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
10.
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03767244
Protocol IDs
CR108535
56021927PCR3011
2018-001746-34
NCI-2019-04921
2018-001746-34
Treatment Sites (2)
11.
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04586231
Protocol IDs
6482-011
MK-6482-011
NCI-2020-11420
2020-002075-35
12.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
13.
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03400332
Protocol IDs
CA027-002
NCI-2018-00525
2018-000340-26
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
15.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCT ID
NCT04322318
Protocol IDs
AREN1921
AREN1921
NCI-2020-01561
Treatment Sites (1)
16.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
17.
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04083976
Protocol IDs
CR108661
NCI-2019-07959
42756493CAN2002
2019-002113-19
Treatment Sites (2)
19.
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04762602
Protocol IDs
2020-306-GLOB2
NCI-2021-01982
20.
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type
Unknown Primary
NCT ID
NCT05263999
Protocol IDs
EQ-100-02
NCI-2022-02430
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05022849
Protocol IDs
CR108972
NCI-2021-12359
75229414MPC1001
22.
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05241834
Protocol IDs
LOXO-NGR-21001
NCI-2022-01823
J3T-OX-JZTA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Cancer Type
Breast Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05307705
Protocol IDs
LOXO-PIK-21001
NCI-2022-04290
2022-000175-40
J4C-OX-JZUA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
26.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT05487170
Protocol IDs
RNK05047-01
NCI-2022-09252
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
28.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT04211337
Protocol IDs
17478
J2G-MC-JZJB
2019-001978-28
NCI-2020-00277
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
29.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
30.
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
Cancer Type
Neuroendocrine Tumor, Prostate Cancer , Unknown Primary
NCT ID
NCT04702737
Protocol IDs
20200040
NCI-2021-08862
31.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05132582
Protocol IDs
SGNTUC-028
NCI-2022-00541
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
32.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05377996
Protocol IDs
MER-XMT-1660-1
NCI-2022-04696
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05002569
Protocol IDs
CA224-098
NCI-2022-02119
2021-001641-13
34.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
35.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
36.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
37.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
38.
A Study to Compare Treatments for a Type of Kidney Cancer called TFE/Translocation Renal Cell Carcinoma (tRCC)
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03595124
Protocol IDs
AREN1721
AREN1721
NCI-2018-01489
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
39.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05581004
Protocol IDs
GO43860
NCI-2022-08852
2021-006708-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
40.
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Cancer Type
Unknown Primary
NCT ID
NCT03763318
Protocol IDs
EQ001-aGVHD-001
NCI-2019-01124
Treatment Sites (1)
41.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for a Brain Tumor
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
42.
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05169567
Protocol IDs
18238
NCI-2022-05155
2021-002301-10
I3Y-MC-JPEF
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
43.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
44.
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCT ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
45.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
46.
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04105010
Protocol IDs
DZ2019J0005
NCI-2021-03769
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
47.
NCORP Trial
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04729608
Protocol IDs
AVB500-OC-004
GOG-3059
NCI-2021-05984
AXLerate-OC
ENGOT OV66
Treatment Sites (1)
48.
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04264702
Protocol IDs
20-041-NCP
NCI-2020-03933
49.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
WINSHIP5566-22
NCI-2022-02855
STUDY00004187
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
Treatment Sites (1)
51.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05039073
Protocol IDs
WINSHIP5260-21
NCI-2021-01655
STUDY00002348
Treatment Sites (2)
52.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
NCI-2013-01275
U10CA021115
E4412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
53.
Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03534804
Protocol IDs
HCI104688
NCI-2018-02081
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
54.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
55.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
56.
Carboplatin and Paclitaxel with or without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT02876107
Protocol IDs
2016-0177
NCI-2017-00619
57.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCT ID
NCT02445222
Protocol IDs
CCTL019A2205B
NCI-2015-01238
2014-001673-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
58.
NCORP Trial
CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04455750
Protocol IDs
A031902
NCI-2020-02360
A031902
Treatment Sites (1)
59.
CD40 Agonistic Monoclonal Antibody APX005M in Treating Pediatric Patients with Recurrent or Refractory Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT03389802
Protocol IDs
PBTC-051
PBTC-051
NCI-2017-01235
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
60.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
61.
Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03493425
Protocol IDs
EA3163
NCI-2017-01364
EA3163
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
62.
NCORP Trial
Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04068103
Protocol IDs
NRG-GI005
NRG-GI005
NCI-2019-01068
Treatment Sites (1)
63.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
64.
NCORP Trial
Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT02567435
Protocol IDs
ARST1431
NCI-2015-01644
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
65.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02997228
Protocol IDs
NRG-GI004
NRG-GI004
NCI-2016-01961
NRG-GI004/S1610
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
66.
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05050162
Protocol IDs
NRG-HN009
NRG-HN009
NCI-2021-08925
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
67.
Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT01993810
Protocol IDs
RTOG-1308
RTOG-1308
NCI-2013-01850
RTOG 1308
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
68.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCT ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
69.
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03678025
Protocol IDs
S1802
S1802
NCI-2018-01738
Treatment Sites (2)
70.
Comparing Two Methods to Follow Patients with Pancreatic Cysts
Cancer Type
Unknown Primary
NCT ID
NCT04239573
Protocol IDs
EA2185
EA2185
ECOG-ACRIN-EA2185
NCI-2019-04790
71.
NCORP Trial
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT04233866
Protocol IDs
EA2186
EA2186
NCI-2019-08286
Treatment Sites (1)
72.
Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type
Gallbladder Cancer, Unknown Primary
NCT ID
NCT04559139
Protocol IDs
EA2197
EA2197
NCI-2020-05162
73.
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer, CISTO Study
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT03933826
Protocol IDs
RG1121143
NCI-2020-06082
74.
Computer Training Program for Younger Patients with a Brain Tumor Who Underwent Radiation Therapy
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT01503086
Protocol IDs
ACCL10P1
ACCL10P1
COG-ACCL10P1
NCI-2012-00112
CDR0000721387
COG-ACCL10P1
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
75.
Curcumin in Treating HIV Infected and Uninfected Women with High Grade Cervical Squamous Intraepithelial Neoplasia
Cancer Type
Unknown Primary
NCT ID
NCT02944578
Protocol IDs
EU2971-15
NCI-2016-01405
IRB00079183
Treatment Sites (3)
76.
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT03904862
Protocol IDs
PBTC-053
PBTC-053
NCI-2019-00180
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
77.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
78.
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04203901
Protocol IDs
CMN-001-1
NCI-2020-07747
79.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04567420
Protocol IDs
DARE
NCI-2021-03770
80.
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCT ID
NCT03397706
Protocol IDs
VT3996-201
NCI-2018-00416
81.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
82.
NCORP Trial
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04137107
Protocol IDs
A221805
A221805
A221805
NCI-2019-04727
83.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
84.
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Cancer Type
Anal Cancer, Unknown Primary
NCT ID
NCT04444921
Protocol IDs
EA2176
EA2176
NCI-2020-04334
85.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03322891
Protocol IDs
HU-HEALTHLITERACY
NCI-2018-00842
IRB00091879
IRB00085616
Treatment Sites (4)
86.
NCORP Trial
Effect of Treatment on Work Experience in Patients with Stage I-III Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03963739
Protocol IDs
WF-1802
WF-1802
WF-1802
NCI-2018-03915
Treatment Sites (1)
87.
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Cancer Type
Unknown Primary
NCT ID
NCT03640481
Protocol IDs
KD025-213
NCI-2018-02858
Treatment Sites (1)
88.
NCORP Trial
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT01349881
Protocol IDs
S0820
U10CA037429
NCI-2012-02067
Treatment Sites (8)
Dwight David Eisenhower Army Medical Center
Augusta
Erik Rupard
706-787-2100
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89.
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT04223856
Protocol IDs
SGN22E-003
NCI-2020-01070
2019-004542-15
MK-3475-A39
Treatment Sites (1)
90.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
91.
Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT02759549
Protocol IDs
WCI1651-09
NCI-2016-00824
IRB00028295
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
92.
NCORP Trial
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses or Partner Caregivers
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04960787
Protocol IDs
S1912CD
S1912CD
SWOG-S1912CD
NCI-2021-00579
Treatment Sites (1)
93.
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04761601
Protocol IDs
UCT01097-001
NCI-2021-02135
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
94.
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05103046
Protocol IDs
UCT03008-001
NCI-2021-14000
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
95.
Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04750473
Protocol IDs
WINSHIP4933-19
NCI-2020-00366
96.
Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03762759
Protocol IDs
RAD4516-18
NCI-2018-02702
IRB00106863
Treatment Sites (3)
97.
Gene Expression in Blood Samples from High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
98.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT03994796
Protocol IDs
A071701
A071701
NCI-2019-00744
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
99.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
100.
Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
101.
Imiquimod, Fluorouracil, or Observation in Treating Patients with High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive
Cancer Type
Anal Cancer, Unknown Primary
NCT ID
NCT02059499
Protocol IDs
AMC-088
NCI-2013-02288
AMC-088
Treatment Sites (1)
Georgia Cancer Center for Excellence at Grady
Atlanta
Scott Edelman
404-489-9000
102.
NCORP Trial
Improving Patient-Centered Communication in Breast Cancer through Patient and Provider Interventions, SHADES Study
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04549571
Protocol IDs
A231901CD
A231901CD
A231901CD
NCI-2020-06176
Treatment Sites (1)
103.
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT02135042
Protocol IDs
NRG-HN001
U10CA021661
U10CA180868
NCI-2014-00635
RTOG-1305
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
104.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
105.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
106.
Integrated Telehealth or In-Person Palliative Care in Improving Quality of Life in Patients with Advanced Non-small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT03375489
Protocol IDs
17-484
NCI-2018-00225
Treatment Sites (1)
107.
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IVB Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01893307
Protocol IDs
2012-0825
NCI-2013-01879
108.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Plasma cell neoplasm, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
109.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Mesothelioma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
111.
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04393350
Protocol IDs
Winship4955-20
NCI-2020-01064
112.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
113.
Leveraging Mobile Health for the Improvement of Oral Chemotherapy Adherence among Women with Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05086731
Protocol IDs
EU5395-21
NCI-2021-09125
114.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Cancer Type
Unknown Primary
NCT ID
NCT03435796
Protocol IDs
GC-LTFU-001
NCI-2018-00957
U1111-1206-8250
2017-001465-24
115.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type
Unknown Primary
NCT ID
NCT03486873
Protocol IDs
3475-587
2017-004417-42
NCI-2018-01717
MK-3475-587
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
116.
Low Dose Y90 Microspheres for the Planning of Radioembolization Therapy in Patients with Stage A-C Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCT ID
NCT04172714
Protocol IDs
RAD4784-19
NCI-2019-06505
IRB00112192
Treatment Sites (3)
Emory Clinic
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
117.
NCORP Trial
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT01901094
Protocol IDs
A011202
U10CA031946
NCI-2013-00875
Treatment Sites (2)
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
118.
Maintenance Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02498951
Protocol IDs
IRB00011601
NCI-2015-01014
ML29496
119.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03053193
Protocol IDs
FLEX Registry
NCI-2018-02995
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
120.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
121.
Mindfulness-based Smoking Cessation Enhanced With Mobile Technology
Cancer Type
Unknown Primary
NCT ID
NCT04965181
Protocol IDs
R01CA237004
NCI-2021-08950
122.
Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04676087
Protocol IDs
WINSHIP5101-20
NCI-2020-06013
123.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT03150914
Protocol IDs
RLDC5713
NCI-2019-08422
U01HL131755-01
Treatment Sites (1)
125.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
126.
Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Neuroendocrine Tumor, Penile Cancer, Prostate Cancer , Unknown Primary
NCT ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
127.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
128.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
129.
NCORP Trial
Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
130.
NCORP Trial
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04181060
Protocol IDs
EA5182
EA5182
NCI-2019-07941
Treatment Sites (1)
131.
Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT04524702
Protocol IDs
Winship5079-20
NCI-2020-05417
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
132.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT02343224
Protocol IDs
IRB00074563
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
133.
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03833167
Protocol IDs
3475-630
KEYNOTE-630
2018-001974-76
NCI-2019-01629
MK-3475-630
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
134.
Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03598998
Protocol IDs
17501
NCI-2018-01420
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
135.
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03030378
Protocol IDs
10061
10061
NCI-2017-00091
HCC 17-003
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
136.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
137.
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Cancer Type
Unknown Primary
NCT ID
NCT04731376
Protocol IDs
EU5097-20
NCI-2020-06998
138.
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05037149
Protocol IDs
SRN-707-001
NCI-2022-02026
139.
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03510104
Protocol IDs
2843-1001
NCI-2018-01102
Treatment Sites (1)
140.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03785249
Protocol IDs
849-001
NCI-2019-01032
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
141.
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04793958
Protocol IDs
849-010
NCI-2021-03009
KRYSTAL-10
142.
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04964934
Protocol IDs
D8534C00001
NCI-2022-01653
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
143.
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Cancer Type
Brain & Spinal Cord Tumor, Lung Cancer, Unknown Primary
NCT ID
NCT02831959
Protocol IDs
EF-25 METIS
NCI-2017-00033
EF-25
144.
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04365374
Protocol IDs
GTM-102
NCI-2021-03480
145.
NCORP Trial
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Solid Tumor, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
146.
Proof-of-concept Trial of Apraglutide in GVHD
Cancer Type
Unknown Primary
NCT ID
NCT05415410
Protocol IDs
TA799-101
NCI-2022-05062
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
147.
Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
148.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
149.
NCORP Trial
Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03598257
Protocol IDs
S1706
S1706
NCI-2018-01519
Treatment Sites (1)
150.
Reaching Rural Cancer Survivors Who Smoke
Cancer Type
Unknown Primary
NCT ID
NCT05008848
Protocol IDs
A211901
A211901
A211901
NCI-2021-03543
151.
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
Treatment Sites (1)
152.
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04922307
Protocol IDs
VICCURO2114
NCI-2021-10595
153.
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Liver Cancer / Hepatoblastoma, Solid Tumor, Unknown Primary
NCT ID
NCT04526106
Protocol IDs
RLY-4008-101
NCI-2020-06870
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
154.
Regorafenib, with Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04117945
Protocol IDs
ACCRU-GI-1809
NCI-2019-06518
155.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
156.
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
Cancer Type
Unknown Primary
NCT ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
157.
Siltuximab and Spartalizumab in Treating Participants with Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT04191421
Protocol IDs
Winship4463-18
NCI-2018-01793
IRB00105616
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
158.
Smoke-Free Homes Intervention for the Prevention of Smoking
Cancer Type
Unknown Primary
NCT ID
NCT04547686
Protocol IDs
SFH-5A-RCT
NCI-2021-01784
STUDY00001085
159.
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients with Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04908709
Protocol IDs
RAD4500-18
NCI-2018-02065
IRB00106849
160.
Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT03550391
Protocol IDs
CCTG CE.7
CE.7
CCTG CE.7
NCI-2018-00395
Treatment Sites (2)
161.
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04050436
Protocol IDs
RPL-002-18
NCI-2019-06779
162.
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT03847519
Protocol IDs
ADXS-503-101
NCI-2019-01784
Treatment Sites (1)
163.
Study of ASN004 in Patients With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04410224
Protocol IDs
ASN004-101
NCI-2022-03443
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
164.
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
165.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05238922
Protocol IDs
INCB 123667-101
NCI-2022-03370
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
166.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04699188
Protocol IDs
CJDQ443A12101
NCI-2021-01594
167.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Cancer Type
Cervical Cancer, Unknown Primary
NCT ID
NCT03108495
Protocol IDs
C-145-04
NCI-2017-01051
2016-003447-11
Treatment Sites (1)
168.
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04123366
Protocol IDs
7339-007
NCI-2019-08758
2019-001745-40
MK-7339-007
KEYLYNK-007
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
169.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type
Unknown Primary
NCT ID
NCT03547973
Protocol IDs
IMMU-132-06 - TROPHY U-01
NCI-2018-03421
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
170.
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04821622
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
171.
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Cancer Type
Breast Cancer, Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04726332
Protocol IDs
XL102-101
NCI-2021-03620
172.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05433142
Protocol IDs
XmAb819-01
NCI-2022-05582
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
173.
Study to Evaluate the Safety and Efficacy of Magrolimab Combination Therapy in Adults With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04958785
Protocol IDs
GS-US-586-6144
NCI-2022-00926
2021-001074-27
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
174.
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04428788
Protocol IDs
CC-94676-PCA-001
NCI-2020-13275
U1111-1251-9174
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
175.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
176.
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02468024
Protocol IDs
SCCC-02515; STU 022015-069
NCI-2015-01676
Treatment Sites (1)
177.
Telotristat Ethyl in Promoting Weight Stability in Patients with Recurrent Advanced Pancreatic Adenocarcinoma
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT03910387
Protocol IDs
Winship4441-18
NCI-2018-01977
IRB00105292
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
178.
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT03141684
Protocol IDs
10005
NCI-2016-01040
17-C-007
CC 17-C-0074
17-C-0074
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
179.
NCORP Trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01810913
Protocol IDs
RTOG 1216
NCI-2013-00500
U10CA021661
Treatment Sites (2)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
180.
NCORP Trial
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
181.
NCORP Trial
Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery, STAMP Study
Cancer Type
Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03712605
Protocol IDs
EA6174
EA6174
NCI-2018-02217
Treatment Sites (1)
183.
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03984448
Protocol IDs
A051701
A051701
NCI-2019-03711
Treatment Sites (2)
184.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
185.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04803201
Protocol IDs
A051902
A051902
NCI-2021-01380
Treatment Sites (2)
186.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
187.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
188.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04134260
Protocol IDs
NRG-GU008
NRG-GU008
NCI-2019-06838
190.
Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and/or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT04201457
Protocol IDs
PBTC-055
PBTC-055
NCI-2019-06216
191.
Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCT ID
NCT05040360
Protocol IDs
S2104
S2104
NCI-2021-06619
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
192.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
193.
NCORP Trial
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04396860
Protocol IDs
NRG-BN007
NRG-BN007
NCI-2020-03404
Treatment Sites (1)
194.
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04852887
Protocol IDs
NRG-BR007
NRG-BR007
NCI-2021-00222
<